-
Some Newer Contraceptive Methods Such As NuvaRing And YAZ / Yasmin Are Under Increasing Scrutiny Over In Europe
Is The FDA Doing Enough About Birth Control Products That Contain Third Generation Or Fourth Generation Progestins And Are Associated With Higher Risks Of Blood Clots (Posted by Tom Lamb at DrugInjuryWatch.com) A January 3,…
-
December 2012 Pradaxa Label Change: Contraindication: Use By Mechanical Heart Valves Patients
A Look At The Events And The Evidence Leading Up To This Latest FDA Action Concerning The Safety Of Pradaxa (Posted by Tom Lamb at DrugInjuryWatch.com) We set the stage with this December 19,…
-
Despite FDA Regulations, Generic Drug Labels Often Failed To Match Brand Name Drug Safety Warnings
Two-Thirds Of The Generics Did Not Have Identical Labeling, And Up To 9% Showed Differences Of More Than 10 Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) A disturbing new study about drug labeling for generic medications…
-
December 2012 Pradaxa Update: Prescription / Sales Numbers And Drug Company Safety Study Results
It Has Been Far From Smooth Sailing For Pradaxa During The Two Years It Has Been Available In The United States (Posted by Tom Lamb at DrugInjuryWatch.com) As we reported in this earlier article,…
-
Generic Drugs Post-Mensing Ruling: One Proposed Solution To The Legal Compensation And FDA Drug Safety Problems Supreme Court Created
At Least, This November 2012 Article In The New England Journal Of Medicine Makes The Point That Something Needs To Be Done Soon, Rather Than Later (Posted by Tom Lamb at DrugInjuryWatch.com) The June 2011…
-
November 2012 Litigation And Settlements Update: YAZ, Yasmin, Ocella, And Gianvi Lawsuits
Bayer Has Settled Less Than Half The DVT And PE Blood Clot Claims Filed Or Cases Subject To Tolling Agreements (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2012 we received the Bayer Stockholders’ Newsletter…